Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Genomic Testing: Sarcoma, Lung Cancer and Thyroid Cancer

April 19th 2019

Genomic Testing: GI Tumors

April 19th 2019

Managing Patients on TRK Inhibitors

April 19th 2019

Entrectinib as Treatment for NTRK-Positive Solid Tumors

April 19th 2019

Larotrectinib for Solid Tumors With NTRK Gene Fusions

April 19th 2019

TRK Inhibitors for Solid Tumors: Overview

April 19th 2019

Detecting NTRK Gene Fusions

April 19th 2019

Precision Medicine: Identifying Actionable Biomarkers

April 19th 2019

NTRK Gene Fusions in Solid Tumor Malignancies

April 19th 2019

Precision Medicine for Solid Tumors: Where We Are Headed

April 19th 2019

Significance of TRK Inhibitors for Solid Tumors

April 19th 2019

Precision Medicine in Solid Tumor Malignancies

April 19th 2019

FDA Expands Approval of PD-L1 IHC 22C3 pharmDX Assay in NSCLC

April 17th 2019

The FDA has expanded the approval of the PD-L1 IHC 22C3 pharmDX assay, allowing the test to be used as a companion diagnostic to identify more patients with stage III or metastatic non–small cell lung cancer who can undergo first-line treatment with pembrolizumab (Keytruda).

Personalized Medicine Progressing in Premenopausal Breast Cancer

April 17th 2019

Joyce A. O’Shaughnessy, MD, discusses the clinical implications of the TEXT and SOFT trials for women with premenopausal HR-positive, HER2-negative breast cancer, as well as unanswered questions that remain with adjuvant endocrine therapy.

Liquid Biopsies Reliably and Quickly Detect Genomic Biomarkers in Metastatic NSCLC

April 17th 2019

Vassiliki A. Papadimitrakopoulou, MD, highlights the implications of the NILE study on clinical practice and sheds light on the potential future utility of liquid biopsies in non–small cell lung cancer.

Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer

April 16th 2019

Mariana Chavez Mac Gregor, MD, MSc, discusses the optimal applications of these assays in patients with early-stage, HR-positive/HER2-negative breast cancer and shed light on the overall outlook of personalized medicine in this setting.

Dr. Chavez Mac Gregor on Chemotherapy in Node-Positive HR+/HER2- Breast Cancer

April 16th 2019

Mariana Chavez Mac Gregor, MD, MSc, associate professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses the use of chemotherapy in patients with node-positive, hormone receptor (HR)-positive, HER2-negative breast cancer.

Dr. Strickler on Genomic Variants Detected by Liquid Biopsies in GI Cancers

April 4th 2019

John Strickler, MD, assistant professor of medicine, Duke Cancer Institute, discusses genomic variants that can be detected by liquid biopsies in patients with gastrointestinal cancers.

Implications for Systemic Therapy in Breast Cancer

March 29th 2019

Novel Therapies in TNBC: Real-World Experience

March 29th 2019